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TheMaraviroc Switch collaborative study (MARCH) is a study in aviremic patients on stable antiretroviral therapy and utilizes
population-based sequencing of proviral DNA to determine HIV tropism and susceptibility to maraviroc. An external quality
assessment (EQA) programwas implemented to ensure competency in assessing the tropism of clinical samples conducted by
MARCH laboratories (n 14). TheMARCH EQA has three prestudy phases assessing V3 loop sequencing and tropism determi-
nation using the bioinformatic algorithm geno2pheno, which generates a false-positive rate (FPR). DNA sequences with low
FPRs are more likely to be from CXCR4-using (X4) viruses. Phase 1 of the EQA involved chromatogram interpretation. Phases 2,
2/3, and 3 involved patient and clonal samples. Clinical samples used in these phases were from treatment-experienced HIV-
infected volunteers; 18/20 had viral loads of<50 copies/ml, and 10/15 were CXCR4-tropic on prior phenotyping. All samples
were tested in triplicate, and any replicate with a geno2pheno FPR of<10%was designated X4. Performance was deemed ade-
quate if<2 R5 and<1 X4 specimens were miscalled. For several clinical samples in the EQA, triplicate testing revealed marked
DNA variability (FPR range, 0 to 96.7%). Therefore, a consensus-based approach was employed for each sample, i.e., a median
FPR across laboratories was used to define sample tropism. Further sequencing analysis showedmixed viral populations in the
clinical samples, explaining the differences in tropism predictions. All laboratories passed the EQA after achieving predefined
competence thresholds in either of the phase 2 rounds. The use of clinical samples from patients resembling those who were
likely to be screened in theMARCH, coupled with triplicate testing, revealed inherent DNA variability that might have been
missed if single or duplicate testing and/or clonal samples alone were used. These data highlight the importance of intensive
EQA of tropism laboratories before embarking on clinical studies. (This study has been registered at ClinicalTrials.gov under
registration no. NCT01384682 [http://www.clinicaltrials.gov/ct2/show/study/NCT01384682?termNCT01384682&rank1].)
Maraviroc (MVC), an approved antiviral agent for the treat-ment of HIV-1 infection, is a small molecule blocker to re-
ceptor 5 of the CC chemokine (CCR5) group (1). MVC is a host-
directed therapy and is an effective antiviral agent in combination
with other antiretroviral agents in patients identified as having a
CCR5-tropic (R5) virus (2).
The sensitivity of the host’s HIV to CCR5 antagonists, includ-
ingMVC, has been determined using a variety of testing platforms
for the assessment of viral tropism. The most widely utilized test
for tropism is the phenotypic recombinant virus assay, the en-
hanced-sensitivity Trofile assay (ESTA) (3). The assay is typically
performed in viremic patients (ideally those with1,000 copies/
ml) and can accurately discriminate between MVC responders
and nonresponders (4).
Genotypic tropism testing using proviral DNA is increasingly
available. A prediction of the likely coreceptor usage of a patient’s
viral population is determined through the amplification, se-
quencing, and analysis of the HIV env V3 loop followed by Web-
based bioinformatic algorithms, e.g., geno2pheno [coreceptor]
(5) or the position-specific scoring matrix (PSSM) (6). However,
there is still a paucity of prospective data on the clinical cutoffs that
should be applied using this tropism testing platform. Data from
retrospective reanalysis of the MVC licensing studies suggest a
geno2pheno false-positive rate (FPR) cutoff of approximately
5.75% (7, 8), while the European Consensus Group guidelines (9)
recommend cutoffs as high as 20% in some cases. Furthermore,
these cutoffs were optimized with data from plasma-based ap-
proaches, but genotypic tropism testing can also be performed
using proviral DNA (10–14).
Despite the lack of validation for tropism testing of proviral
DNA in aviremic patients exposed to MVC, recent European
Consensus Group guidelines (9) have been published recom-
mending how many times a patient sample should be sequenced
(single, duplicate, or triplicate) and how the geno2pheno FPR
should be applied to define tropism in aviremic individuals. For
population genotyping using proviral DNA, the study group rec-
ommended FPR cutoffs of 10% or 20% in triplicate and single
testing, respectively (9). DNA sequences with FPRs below the cut-
off are classified as being from CXCR4-using (X4) viruses.
The Maraviroc Switch collaborative study (MARCH)
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.clinicaltrials.gov/ct2/show/study/NCT01384682?termNCT013
84682&rank1) is an ongoing international randomized clinical
trial of MVC as a replacement for the current nucleoside or nu-
cleotide analogue reverse transcriptase inhibitor or boosted pro-
tease inhibitor (PI/r) in virologically suppressed subjects (plasma
viremia 200 copies/ml) on a stable PI/r-based therapy. Partici-
pants are only eligible if they have R5HIV as assessed by genotypic
testing using proviral DNA. The study is being conducted in 62
sites across Europe (n 27), Australia (n 11), Asia (n 2), and
North (n  4) and South (n  18) America, and 14 laboratories
are involved in the study.
When the study was established in 2011, one of the challenges
was the lack of a standardized international quality assurance or
quality control program for the assessment of tropism using pro-
viral DNA across the network of international laboratories serving
the sites in which the MARCH was being conducted. The aim of
this paper is to describe the experience of the MARCH laboratory
group in establishing and completing an external quality assess-
ment (EQA) program prior to testing participant samples in the
MARCH.
Laboratory methods. Each of the 14 laboratories performing
genotypic tropism testing for the MARCH uses its own in-house
methodology. There are, however, some key commonalities
among these methods, and a representative method is detailed in
Swenson et al. (13). In this EQA program, the starting material is
DNA (see below). The V3 region of HIV gp120 is amplified in
triplicate by PCR and is sequenced by standard population-based
sequencing. The resulting chromatograms are analyzed either
manually by technicians or automatically using the freely accessi-
ble software RECall (15), with no manual inspection. These se-
quences are then submitted to the geno2pheno algorithm for tro-
pism interpretation. Geno2pheno converts an input V3 sequence
to an FPR value. This FPR is related to the likely phenotypic tro-
pism that is associated with the submitted sequence (5). Initially,
an FPR of20%was used to determine R5 versus X4, but this was
lowered to 10% after completion of phase 2/3 (see below). In
summary, samples were classified as R5 only if all three sequences
had an FPR of10%, and the samples were classified as X4 if they
had an FPR of 10%; samples that were unable to be amplified
were classified as a fail.
External quality assessment methods. The objective of the
EQA was to ensure uniformity, reproducibility, and competency
inDNA-basedHIV tropism testing by the laboratories involved in
the MARCH. There were four phases of EQA for the tropism
laboratories in the MARCH (Fig. 1), and all phases were overseen
by NRL, Victoria, Australia. Laboratories having performance is-
sues in any of the phases were contacted to identify areas of im-
provement (e.g., were encouraged to use RECall), such that an
increasing number of laboratories were able to meet competency
criteria in subsequent EQA phases.
The purpose of phase 1 was to assess laboratory proficiency in
the sequence interpretation steps, from processing the raw se-
quence chromatogram to interpreting with the geno2pheno algo-
rithm. The NRL distributed identical sets of sequence chromato-
gram files corresponding to 10 samples sourced from the
Vancouver and Cologne laboratories. The samples were selected
such that five had FPRs of 20% and five had FPRs of 20%.
The laboratories then analyzed the chromatograms manually
or automatically, and they submitted the resulting sequences to
geno2pheno for interpretation. A tropism classification was de-
termined for each of the 10 specimens, and these results were
returned toNRL. To pass phase 1, each laboratory was required to
achieve the same results as those of the reference laboratory on all
10 sets of chromatograms.
The aim of phase 2 was to assess all the steps required for
DNA-based genotypic tropism testing. This phase involved test-
MARCH study
QA/QC programme for HIV co-receptor tropism assay
Idenfy Reference and Tropism laboratories
3 step QA/QC programme
Phase 1: Chromatogram Interpretaon
Phase 2: Analysis of Clinical Samples
Phase 3: On Study Assessment of QA 
Proﬁciency 
Proceed with tesng 
MARCH study samples
Criteria:
•Interpret 10 chromatograms from 
reference lab.
•All tropism labs to parcipate.
•TAT = 10 working days from receipt of 
data.
100% concordance
Criteria:
•Test panel of 20 DNA samples for 
tropism 
•All tropism labs to parcipate.
•TAT = 28 days from receipt of samples.
Criteria:
•Test a panel of 12 DNA samples- 10 clinical 
samples and 2 clonal samples.
•All tropism labs to parcipate.
•TAT = 14 working days from receipt of the panel.
•Assessment will occur every 6 months unl 
enrolment is completed.
•Competency = consensus based result and each 
lab allowed 1 incorrect X4 and 2 incorrect R5.
Hybrid Phase 2/3: Analysis of 
Clinical Samples
All labs to parcipate in order to qualify 
against the new consensus criteria.
•Test a panel of 12 DNA samples- 10 samples 
are from Phase 2, and 2 are clonal samples.
•TAT = 28 working days from receipt of the 
panel.
•Competency on the samples from Phase 2 = 
1 incorrect X4 and/or 2 incorrect R5, both 
clonalsamples must be correctly idenﬁed. 
FIG 1 Summary of the EQA program for the MARCH HIV coreceptor tropism assay. TAT, turnaround time.
Tu et al.
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ing 20 DNA samples derived from clinical specimens. Eighteen of
the samples were from treatment-experienced patients with viro-
logic suppression (plasma viremia,50 copies/ml) on combina-
tion antiretroviral therapy (cART) for 6 months. Patient sam-
ples for phase 2 were selected from a patient populationmirroring
the profiles of likely MARCH participants. Moreover, the selec-
tion was weighted toward “known” X4 tropism (in 10/15) on
prior phenotypic testing prior to virologic suppression, as it was
felt that the ability to detect X4 was more important than the
ability to detect R5, the former being a safety issue for a potential
MVC switch.
To have sufficient starting material for all laboratories, each
was sent specimens containing 2 to 8 g purified DNA in 50 l of
nuclease-free water. All laboratories were instructed to test each
sample in triplicate. TheV3 regionwas PCR amplified, sequenced,
interpreted, and analyzed using geno2pheno. A sample was clas-
sified as X4 if any of the 3 amplicons had a geno2pheno FPR below
the classification cutoff (either 10% or 20%). For comparisons
among the laboratories, a consensus-based approach was used to
establish the “correct” classification of a sample; this was necessary
due to the inherent variabilities of the clinical specimens. In this
scheme, the consensus value for each sample was set as themedian
of the lowest FPR from each laboratory, and if this fell below the
cutoff, then the consensus classification for that sample was X4.
For example, if a sample had a median FPR of 5%, the reference
tropism classification for this sample would be X4.
For phase 2, samples forwhich themedian interlaboratory FPR
was20%were calledX4, but this cutoff was subsequently revised
to10% (see Results). Of the 20 samples, a maximum of 3 incor-
rect tropism classifications were permitted: up to 2 R5 samples
could be incorrectly called X4, and 1 X4 sample could be incor-
rectly called R5. These criteria allowed for the variability of clinical
specimens (i.e., permitting 3 samples per laboratory to be classi-
fied differently from the consensus), while remaining conservative
(i.e., only one “missed” X4was permitted). Laboratories were also
required to successfully obtain sequences from 80% of samples
(16 of 20).
Because of the revised cutoff and the establishment of compe-
tency criteria in phase 2, another EQA phase (called hybrid phase
2/3) was implemented to test these as prespecified criteria. The
phase included 10 of the original clinical specimens, plus 2 clonal
specimens (1 X4 and 1 R5). To pass hybrid phase 2/3, laboratories
were required to pass the prespecified criteria for the clinical spec-
imens and to correctly classify both clonal samples. Laboratories
that successfully passed phase 2 and/or the hybrid phase could
begin testing the enrolled participants in the MARCH. An ongo-
ing phase 3 will occur every 6 months during the screening phase
of the MARCH and will comprise testing of the original clinical
samples, plus 2 clonal samples (Fig. 1). Data from phase 3 are not
currently available and are not discussed here.
Further investigations. In addition to the EQAmethodology,
further investigations were performed to estimate the variation
within samples, as well as to estimate the effect of manual versus
automated sequence analysis. For estimating variation, all 20
phase 2 samples were repeatedly amplified to a maximum of 32
sequences per sample. Each sequence was scored by geno2pheno.
The median and interquartile range of the FPR for each sample
were also quantified. Furthermore, seven samples from the hybrid
phase 2/3 underwent deep sequencing on a Roche/454 Genome
Sequencer Junior.
To determine whether manual sequencing analysis had an im-
pact on the results, raw chromatogram files were requested from
the laboratories participating in the hybrid phase 2/3 and were
processed usingRECall. These chromatogramfileswere generated
independently at each laboratory using their own methodologies.
Processing the raw files with RECall eliminated variability in the
sequencing analysis and in the interpretation step of the protocol,
such that any variation observed could be attributed only to the
amplification and the sequencing steps.
The nucleotide sequences obtained by all laboratories partici-
pating in phase 2 (triplicate testing) were analyzed using phyloge-
netic analysis. The alignment and phylogenetic analysis were per-
formed using ClustalX.
RESULTS
All laboratories met competency criteria in phase 1 of the EQA
for tropism testing in the MARCH, confirming their profi-
ciency in obtaining inferred tropism results from raw sequence
chromatogram files. This phase also confirmed that these steps
of genotypic tropism testing are reproducible across different
settings.
Subsequent phases of the EQA showed more variability be-
tween laboratories, which is likely due to variation introduced by
the sample handling, amplification, sequencing, interpretation
steps, and biological variation (16). Of the 15 laboratories that
passed phase 1, 14 laboratories participated in subsequent EQA
phases, and one laboratory withdrew participation from the EQA
program.
Laboratories participating in phase 2 returned more variable
results than those in phase 1 (Fig. 2). Twenty DNA samples were
distributed, of which 19 were successfully amplified by the major-
ity of laboratories. One laboratory only successfully amplified and
sequenced 15/19 samples. Phase 2 initially used an FPR cutoff of
20% and allowed 3 incorrectly classified samples (2 R5 samples
called X4 and 1 X4 sample called R5).
Based primarily on the analysis of a subset of patients in the
Maraviroc Therapy in Antiretroviral Treatment-Experienced
(MOTIVATE) and A4001029 trials of maraviroc (17), the
geno2pheno cutoff was lowered to 10%. This was based partially
on the finding that an FPR of 10% outperformed an FPR of 20%
for distinguishing between the responders and nonresponders to
maraviroc (see supplementary Fig. 1 of reference 17). Using the
altered cutoff, there were fewer incorrect X4 classifications per
laboratory (mean of 1.54 with a cutoff of 20% versus a mean of
1.38 with cutoff of 10%). On average, each laboratory misclassi-
fied amedian of 1 R5 sample (interquartile range [IQR], 1 to 1.75)
and 1 X4 sample (IQR, 1 to 3) in phase 2. A total of 7 laboratories
were deemed appropriate to open for tropism testing after meet-
ing the competency criteria in phase 2.
The competency criteria established in phase 2 were then ap-
plied in hybrid phase 2/3 (Table 1). In this phase, laboratories
misclassified a median of 0 R5 samples (IQR, 0 to 0), and 1 X4
sample (IQR, 0 to 1). All laboratories except one were able to
correctly classify both clonal specimens, a requirement in hybrid
phase 2/3. Based on the phase 2/3 results, a further 3 laboratories
were deemed appropriate to open for testing, in addition to the 7
that were deemed appropriate after phase 2, for a total of 10.
Subsequent analyses. Specimens distributed in phase 2 under-
went repeated amplification and sequencing to a maximum of 32
amplifications per sample in the reference lab, with amedian of 17
MARCH EQA for Proviral DNA Testing for HIV Tropism
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(IQR, 10.5 to 23). The variation detected in these samples is dis-
played in Fig. 3. Twelve of 19 samples appeared to have mixed R5
and X4 populations, according to this repeated sequencing, with a
median of 55% of sequences below an FPR of 10% (IQR, 28 to
75%). These mixed-tropism samples were associated with a
greater number of laboratories giving classifications that were dis-
cordant from the consensus. A median of 14% of laboratories
(IQR, 7 to 10%) gave discordant results in the mixed-tropism
samples, versus amedian of 0% discordant laboratories (IQR, 0 to
21%) where repeated sequencing indicated “pure” R5 or X4 pop-
ulations. Figure 3 shows the sample variation detected by this
method. Seven samples had consistent tropism classifications by
all laboratories, and these appeared to have small interquartile
ranges in the FPRs as detected by repeated sequencing, suggesting
that lower variability might have contributed to the higher inter-
laboratory agreement. Further analysis of the sequences using
phylogenetic analysis revealed that where tropism results dis-
agreed with the consensus, the sequences still clustered closely
with other sequences from the same specimen, suggesting that
sample mix-ups and to a lesser extent contamination, were not
major issues in the EQA. No samples had apparently been
switched at any laboratory, and there were 10 possible contami-
nation events identified out of a total of 685 sequences that were
obtained for phase 2 (Fig. 4).
For phase 2/3, laboratories that classified samples as having
discordant tropism results compared to the consensus were asked
to submit the raw chromatogram files obtained for these samples.
All chromatograms were then interpreted automatically with
FIG 2 Interlaboratory variation in minimum FPR. There was significant variation across the laboratories for each sample, even when the lowest geno2pheno
false-positive rates (FPRs) were examined. Samples were sorted by consensus tropism and then by decreasing interlaboratory agreement. The minimum FPRs
obtained from all laboratories from each of the 20 specimens in phase 2 were used to generate box-and-whisker plots for each specimen. Horizontal lines
represent the median FPR, boxes represent the interquartile range of the values, and whiskers represent the minimum andmaximum values obtained across the
laboratories. One laboratory (laboratory B) gave outlier results for 4 samples (with outlier defined as an FPR outside the rangemean 1.96 standard deviations).
These were samples 1, 3, 8, and 15. The other laboratories contributed 0 to 2 outlier results.
TABLE 1 EQA hybrid phase 2/3 results for the 14 laboratoriesa
Clone or
sample no.
Consensus
classification
FPR (%) at the indicated laboratory
A B C D E F G H I J K L M N
Clone 1 R5 17 8.5 17 17 17 17 17 17 17.9 17 17.9 17 17 17
Sample 3 R5 16.6 5.8 13.2 20.8 13.2 13.2 13.2 16.9 20.7 13.2 16.6 13.1 14.7
Sample 5 R5 47.8 6.8 5.3 47.8 0.4 47.8 47.8 47.8 44.5 47.8 47 47.8 47.8
Sample 6 R5 44.2 5.9 42.6 44.2 44.2 44.2 44.2 44.2 44.2 44.2 44.2 44.2
Sample 7 R5 20.2 15.4 13 13 13 20.2 20.2 20.2 20.2 17.3 13 20.2 16.4
Clone 2 X4 0.1 0 0 0.2 0.1 0 0 0.1 0.2 0.2 0 0 0.2 0.2
Sample 4 X4 2.7 1.7 2.6 2.5 2.6 2.6 2.6 2.6 2.6 2.8 2.6 2.6 2.7 2.6
Sample 8 X4 3.2 1.3 1.7 3.2 19.1 3.2 3.2 34.3 3.8 1.3 1.8 1.2 1.2 1.3
Sample 9 X4 3.1 1.7 1.8 22.4 1.9 2.9 21.2 21.3 6 16.2 1.7 0.7
Sample 10 X4 2.6 1.7 2.6 2.6 2.6 2.6 2.6 3.5 3.2 2.6 3.2 2.6 2.6 2.6
Sample 11 X4 5.3 3.2 4.8 4.1 24 1.7 16.4 1.3 24 4.6 6.7 16.4
Sample 12 X4 7.8 7.8 7.8 7.8 7.8 7.4 7.8 31.1 7.8 7.8 7.8 14.3 7.8
a The lowest FPR results from the triplicate testing for each sample by each laboratory are shown here. The FPR cutoff was 10%. R5 was determined if the FPR was10%, and X4
(shaded cells) was determined if the FPR was10%. Blank boxes indicate that the sample could not be amplified.
Tu et al.
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RECall and were scored with geno2pheno. Applying consistent
base-calling interpretation software resulted in two additional
laboratories meeting the competency criteria in phase 2/3, for a
total of 11. RECall reanalysis corrected a mean of 0.6 sample per
laboratory (range, 1 incorrect sample added by RECall reanalysis
to 3 corrected samples). The coefficient of variation of the
geno2pheno FPRs of the samples was significantly lower after
RECall reanalysis (t test, P  0.04), suggesting decreased inter-
laboratory variability. As a result, all laboratories are now encour-
aged to use RECall in their sequencing analyses.
To further estimate the effect of intrasample diversity on inter-
laboratory concordance, samples from hybrid phase 2/3 (clonal
sample 2, sample 4, and samples 7 through 11) underwent deep
sequencing on a Roche/454 Genome Sequencer Junior. Sequence
depth was a median of 1,877 sequences/sample (IQR, 1,200 to
2,326). The percentage of sequences in the sample scoring10%
by geno2pheno was calculated to quantify the sample diversity.
There were three samples for which deep sequencing indicated
100% of sequences as scoring below a geno2pheno cutoff of 10%
(sample 4, sample 10, and clone 2). Interestingly, these samples
had the highest interlaboratory agreement, with all laboratories
returning X4 results. Similarly, a sample consistently called R5 by
all laboratories (sample 7) had a very low prevalence (2.5%) of
sequences that were 10%. The remaining samples had both
lower interlaboratory agreement and mixed populations of se-
quences above and below the FPR cutoff of 10%, which might
account for the lower agreement. For example, sample 8 had
47.5% of sequences that were 10%, with 86% of laboratories
giving X4 results. Two-thirds of laboratories returned X4 results
for samples 9 and 11, and these samples had 25% and 1.2% of
sequences that were10%, respectively.
DISCUSSION
The traditional structure of an EQA is to discern the ability of the
laboratories to perform a test and to reveal the correct result as
already determined by a reference laboratory or by a “gold stan-
dard.” Tropism laboratories chosen to participate in theMARCH
are experienced in genotypic assessments of tropism using provi-
ral DNA, and they operated using their normal methods. The
major finding through the MARCH EQA was the high variability
within proviral DNA samples when these are derived from pa-
tients with chronic infection who have had prolonged periods of
viral suppression.
In its purest form, an EQA assessing tropism using proviral
DNA could have been performed using only clonal samples to
assess the ability of the laboratories to adequately perform each
step of the method. One might argue that an EQA using only
clonal samples, followed by clinical samples that mirrored likely
participant samples for the MARCH, would have been a better
approach. As participant laboratories were, for the most part, al-
ready experienced in this technology, we chose to use only clinical
samples in the wet panel testing (phase 2). However, the high
variability of the results from phase 2 led to a further round of wet
panel testing using both clonal and clinical samples (phase 2/3
onwards) in order to better understand where discrepancies be-
tween the laboratories had occurred.
One of the major challenges of the EQA program was defining
“truth,” i.e., the correct tropism of the proviral DNA clinical sam-
ples. From the three separate results that were obtained for each
sample, if any sequence was identified as X4, it was reported as X4.
To overcome the partial DNA variability, a consensus-based ap-
proach for tropism determination of a sample was used. The final
correct tropism was defined by what the majority of laboratories
FIG 3 Variation by repeated amplifications. The same specimens shown in Fig. 2 were repeatedly sequenced up to 32 times. For comparison, they are displayed
in the same order as in Fig. 2. The intensive sequencing revealedmarked variationwithin the samples. Horizontal lines represent themedian FPR obtained across
all repeated sequences, boxes represent the interquartile ranges of the values, and whiskers represent the minimum and maximum values obtained by repeated
sequencing. Samples for which all laboratories gave the same tropism determination often had lower variability according to repeated sequencing analysis (see
specimens with asterisks). This approach shows the importance of triplicate sequencing, sincemany samples had large spreads of FPR values (e.g., sample 8). The
method of taking the minimum FPR detected is also key to a sensitive detection of the X4 virus, since higher FPRs might obscure X4 detection (e.g., sample 19).
*, all laboratories called X4; **, all laboratories called R5.
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had called the sample. As a result, the consensus value for each
sample was set as the median of the lowest FPR from each labora-
tory, and if this fell below the cutoff, then the consensus classifi-
cation for that sample was X4.
Furthermore, to establish the factors that are associated with
divergent results across laboratories, the EQA clinical samples un-
derwent repeated amplifications and deep sequencing. Further
analysis revealed a heterogeneous viral populationwithin the clin-
ical samples tested, i.e., amix of R5 andX4 variants. The biological
intrasample variability therefore explains the discordance ob-
served in tropism results across laboratories and within the repli-
cates tested. In addition, the vast majority of sequences clustered
most closely with other sequences from the same specimen, which
in most cases excludes the possibility of contamination. Thus, the
majority of discrepant results likely arose from the random am-
plification ofminority quasi-species andnot frommethodological
deficiencies by the laboratory. Furthermore, this analysis high-
lights the reality that even triplicate testing is not able to suffi-
ciently capture all the diversity that is present in a clinical spec-
imen.
Recent studies support the use of triplicate testing but have
been associated with an increased detection of X4 variants, and
hence, the number of patients eligible for MVC treatment is re-
duced (13, 18, 19). Symons et al. (18) showed that with the addi-
tion of a third replicate, there was a 4% increase in X4 prediction
in the study population, and this resulted in reclassification from
R5 to X4 tropism. Duplicate testing has also been investigated
using plasma HIV RNA and showed improved detection of X4
viruses compared to single testing (20). For the MARCH study,
given the inherent variability of DNA and the clinical outcome
being unknown, we prefer to be conservative and perform tripli-
cate testing at an FPR of 10%. The detection of X4 sequences in
any triplicate amplification from a sample should preclude that
patient from switching to MVC.
Originally, the FPR threshold was set at 20%, which was a con-
servative cutoff. However, considering that the EQAwas set up for
implementation in a large-scale clinical study and potentially in
routine clinical practice, it was critical to be conservative in terms
of safety, i.e., to exclude those patients with X4 virus. The conse-
quence of such a conservative FPRwas that themajority of viruses
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FIG 4 Phylogenetic tree of EQA phase 2 sequences for the 14 laboratories. Each sample is represented by a different color. Inmost cases, the sequences generated
from the same sample by different laboratories clustered near each other. There was no evidence of samplemix-ups according to phylogenetic analysis. There was
evidence of contamination (i.e., a sequence from one sample clustering with another) for 7 laboratories (laboratories A, B, D, F, H, I, and N), with most cases
being restricted to a maximum of 1 sequence in 1 sample. There were 10 possible contamination events identified out of 685 sequences obtained (1.5%).
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had a predicted tropism of X4. According to the European Con-
sensus Group guidelines (9), it is recommended that proviral
DNA tropism testing be performed in triplicate with an FPR of
10%, and the revised cutoff in the MARCH is consistent with that
recommendation. A recent study by Svicher et al. (21) detected
more R5-tropic viruses when an FPR of 10% was used than when
an FPR of 20% was used. To support the use of a lower threshold
and also to improve the detection of CCR5 tropism, an FPR of
20% was compared to FPRs of 2%, 5.75%, and 10% using data
available from a subset of patients in the MOTIVATE and
A4001029 trials (17). The comparison demonstrated that an FPR
of 10% provided a clear discrimination between responders and
nonresponders to MVC-containing regimens, and applying this
to MARCH EQA produced fewer incorrect X4 classifications.
Therefore, the FPR cutoff was revised to 10% for phase 2 onwards.
Several studies have also evaluated the use of lower FPRs at
10%, 5.75%, and 5% to assess the performance of genotypic tro-
pism testing in proviral DNAwith phenotypic tropism testing (10,
22). There was high concordance between the genotypic and phe-
notypic testing at FPRs of 10% and 5.75% of 96.3% and 100%,
respectively (22), and 85% concordance at FPRs of 10% and 5%
(10), which suggests that an FPR of 5.75% might be a good pre-
dictor for a positive response to MVC therapy (7). However, it is
important to consider that these studies examined patients with
detectable viral loads of500 copies/ml, and they used HIV RNA
instead of DNA as their starting material. For the MARCH, given
that the patients are virologically suppressed, there is the potential
to use a lower threshold to predict the clinical efficacy of MVC as
a switch drug, but this would require further validation and as-
sessment of clinical outcomes at lower thresholds, and potentially
another intensive EQA. Once clinical data are available from the
main MARCH, we will be able to perform a retrospective analysis
to determine if a lower FPRwould have a similar clinical efficacy of
MVC at an FPR of 10% and, hence, optimize the use of CCR5
antagonists in a clinical setting.
Intensive quality assessment and quality control (QA/QC) of
all laboratories should be implemented before embarking onmul-
tinational clinical studies in order to ensure that a common stan-
dard is used prior to testing participant samples (23–25). Recently,
the DNA Tropism Italian Validation Concerted Action (DIVA)
study (21) was set up to standardize genotypic tropism testing
using proviral DNA for the routine clinical diagnostic laboratory
in Italy. There were two phases; phase 1 involved the cross-valida-
tion of the methodology of V3 sequencing on proviral DNA
among the 5 reference centers, and phase 2was aimed at validating
and sharing the methodology with 12 local virological centers in-
volved in the project. Patient samples were used, and the majority
had an undetectable viral load of50 copies/ml. A single PCRwas
performed, and a geno2pheno FPR of 20%was applied. The study
demonstrated high concordance in the genotypic tropism predic-
tion using proviral DNA across the different laboratories in Italy
(21). Interestingly, there were only 2 discordant samples between
the local virological centers and the reference center, while in the
current study, the high levels of DNA variation complicated the
tropism prediction. The main difference between the two studies
is that the DIVA study was performed singly versus in triplicate,
and this perhaps resulted in less variability between the laborato-
ries. Other factors that might have contributed to the differences
observed were the sample size tested, the extraction procedure by
which proviral DNA was obtained, the sequencing method used,
the replicates performed, and the FPR cutoff that was applied.
Overall, an EQA program is a useful tool for helping to standard-
ize a methodology in laboratories that do not routinely perform
the testing. Panels should also include patient-derived samples to
best reflect the patient population being tested.
Therefore, the MARCH EQA program of genotypic tropism
testing using proviral DNA revealed the inherent variability of
viral DNA in virally suppressed patients, and if only single or
duplicate replicates had been performed, some of the variability
and random amplification of a minority quasi-species that were
revealed by triplicate testing would have been missed. All labora-
tories involved in the EQA program are now serving as tropism
laboratories testingMARCH participant samples. TheMARCH is
the first randomized multicenter international study of the use of
MVC as a switch drug in virologically suppressed HIV-1-infected
patients. It will provide the largest clinical data set for the efficacy
and safety of this approach, utilizing a genotypic assessment of
tropism on proviral DNA to determine the sensitivity to MVC as
an antiviral agent. As such, a robust determination of viral tropism
is essential to the integrity of this study. The EQA program estab-
lished for the MARCH plays a critical role in ensuring that the
outcome of the study is reliable and applicable for the assessment
of tropism in a clinical setting.
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